ROME -- Gout patients receiving treatment with standard allopurinol therapy appear to have a reduced risk of disease flares if they are treated with the investigative monoclonal antibody canakinumab, researchers said here.
In an interim analysis of a randomized, dose-ranging clinical trial of more than 400 patients, all of those administered canakinumab achieved a superior reduction in gout flares after 16 weeks of therapy compared with those given colchicine 0.5 mg once a day. All the patients were initially treated with allopurinol and had been on treatment with allopurinol for at least one month before entering the trial.
"We did not observe evidence of a dose response with canakinumab," said Naomi Schlesinger, MD, associate professor of medicine at the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, New Brunswick, in a presentation at the 2010 annual meeting of the European League Against Rheumatism.
http://www.medpagetoday.com/Rheumatology/GeneralRheumatology/20776BumpingGood info to know............Moving up to spank the spammers.......TTTspam while annoying is temporaryIn an interim analysis of a randomized, dose-ranging clinical trial of more than 400 patients, all of those administered canakinumab achieved a superior reduction in gout flares after 16 weeks of therapy compared with those given colchicine 0.5 mg once a day. All the patients were initially treated with allopurinol and had been on treatment with allopurinol for at least one month before entering the trial.
"We did not observe evidence of a dose response with canakinumab," said Naomi Schlesinger, MD, associate professor of medicine at the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, New Brunswick, in a presentation at the 2010 annual meeting of the European League Against Rheumatism.